All In Biotech

Drug Trial Radar · NCT05902221

Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 235 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

235

Planned (sponsor's estimate)

Start

May 2, 2024

Primary completion

May 2028

Study completion May 2028

Sponsor

Lead sponsor
Centre Hospitalier Universitaire de NiceAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI). After shoulder prothesis, C. acnes mainly affects hip prosthesis. One recent work from the Lyon (France) bone and joint infections reference center with data focusing mainly on hip and knee PJI has reported that C. acnes is the leading cause of late-onset PJI after coagulase negative staphylococci (CNS) (late acute PJI not considered). In such late-onset device-related infection, biofilm, as produced by C. acnes during PJI represents a major hurdle on the path to patient's cure. Because biofilm-associated bacteria have a slower metabolism and a lower multiplication rate than planktonic bacteria, antibiotic susceptibility can be hampered. Rifampicin is an antibiotic with low minimal bactericidal concentration against S. aureus and CNS biofilm-associated bacteria8 which significantly influence patient's outcome during staphylococci PJI.

Conditions

  • Infections Joint Prosthetic

Interventions

  • amoxicillin or moxifloxacinDrug

    Antibiotic treatment back bone during 12 weeks

  • amoxicillin or moxifloxacin + rifampicinDrug

    Antibiotic treatment back bone during 12 weeks + rifampicin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of C. acnes prosthetic joint infections management failureTime frame: 24 months after the end of antibiotic treatment
  2. Rate of adverse event linked to rifampicinTime frame: during rifampicin treatment

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • CH Annecy Genevois

    Annecy, France · Recruiting

  • CHU de BORDEAUX

    Bordeaux, France · Recruiting

  • Hôpital Ambroise Paré

    Boulogne, France · Recruiting

  • HCL

    Lyon, France · Recruiting

  • AP-HM

    Marseille, France · Not yet recruiting

  • CHU de MONTPELLIER

    Montpellier, France · Recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • CHU de NICE

    Nice, France · Recruiting

  • Dianonesses croix saint simon

    Paris, France · Recruiting

  • CHU de Rennes

    Rennes, France · Recruiting

  • CHU Toulouse

    Toulouse, France · Recruiting

  • Ch Tourcoing

    Tourcoing, France · Recruiting

  • CHRU Tours

    Tours, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.